Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Polioudaki, Hara ^a   Agelaki, Sofia ^a,b   Chiotaki, Rena ^a   Politaki, Eleni ^a   Mavroudis, Dimitris ^a,b   Matikas, Alexios ^b   Georgoulias, Vassilis ^a,b   Theodoropoulos, Panayiotis A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Breast cancer; Circulating tumor cells; EMT; Fluorescence levels of cell markers; Keratin expression levels; Vimentin keratin ratio

Indexed keywords

ESTROGEN RECEPTOR; KERATIN; VIMENTIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; HS578T CELL LINE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOFLUORESCENCE MICROSCOPY; LASER MICROSCOPY; MCF 7 CELL LINE; MDA MB23 CELL LINE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; SINGLE CELL ANALYSIS; T47D CELL LINE; TRIPLE NEGATIVE BREAST CANCER; ADULT; AGED; BREAST TUMOR; FEMALE; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR EMBOLISM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; KERATINS; MCF-7 CELLS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; SURVIVAL ANALYSIS; VIMENTIN; YOUNG ADULT;

EID: 85019240060     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1386-7     Document Type: Article

References (19)

1. Joosse SA, Hannemann J, Spotter J, Bauche A, Andreas A, Muller V, et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res. 2012;18(4):993-1003.
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-8.
3. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11(4):R46.
4. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 2011;130(2):449-55.
5. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580-4.
6. Whipple RA, Balzer EM, Cho EH, Matrone MA, Yoon JR, Martin SS. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 2008;68(14):5678-88.
7. Whipple RA, Matrone MA, Cho EH, Balzer EM, Vitolo MI, Yoon JR, et al. Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res. 2010;70(20):8127-37.
8. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-15.
9. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis. 2008;25(6):629-42.
10. Vergara D, Valente CM, Tinelli A, Siciliano C, Lorusso V, Acierno R, et al. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett. 2011;310(1):1-8.
11. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288(1):99-106.
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.
13. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23(3):618-24.
14. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev. 2002;2(6):442-54.
15. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74.
16. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423-8.
17. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19(11):1438-49.
18. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, et al. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med. 2011;15(5):1066-70.
19. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, et al. Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol. 2011;2011:252361.